Peter Emtage, Santa Ana Bio CEO (Versant)
March 10, 2023 07:30 AM ESTUpdated 07:46 AM
Financing
Startups

Ver­san­t's new im­munol­o­gy biotech San­ta Ana Bio snags Se­ries A with GV, TPG part­ners on board

Kyle LaHucik

Senior Reporter

Pro­lif­ic biotech in­vestor Ver­sant Ven­tures is brew­ing an­oth­er start­up, this time im­munol­o­gy play­er San­ta Ana Bio, whose board in­cludes part­ners from GV and TPG. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times